Regeneron Up Nearly 6%, Best Performer in the Nasdaq 100 So Far Today -- Data Talk
February 25 2020 - 12:06PM
Dow Jones News
Regeneron Pharmaceuticals, Inc. (REGN) is currently at $450.58,
up $25.20 or 5.92%
-- Would be highest close since Oct. 11, 2017, when it closed at
$452.97
-- On pace for largest percent increase since Nov. 5, 2019, when
it rose 6.93%
-- Earlier Tuesday, Evercore ISI Group and Jefferies both
upgraded their rating for Regeneron Pharma, Benzinga reported
-- Novartis' Beovu macular-degeneration treatment had some
concerning safety reports, suggesting that Regeneron's Eylea
alternative could command a greater market share, Barron's
reported
-- Currently up four of the past five days
-- Currently up three consecutive days; up 12.89% over this
period
-- Up 33.33% month-to-date; on pace for best month since Jan.
2012, when it rose 63.92%
-- Up 20% year-to-date
-- Down 23.94% from its all-time closing high of $592.40 on Aug.
5, 2015
-- Would be a new 52-week closing high
-- Up 64.77% from its 52-week closing low of $273.46 on Sept.
27, 2019
-- Traded as high as $454.08; highest intraday level since Oct.
12, 2017, when it hit $454.52
-- Up 6.75% at today's intraday high; largest intraday percent
increase since Nov. 5, 2019, when it rose as much as 10.63%
-- Third best performer in the S&P 500 today
-- Best performer in the Nasdaq 100 today
All data as of 11:27:55 AM
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
February 25, 2020 11:51 ET (16:51 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Oct 2023 to Oct 2024